
Puma Biotechnology (PBYI) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Puma Biotechnology (PBYI) last issued guidance on August 6, 2026 for Q3 2026. The company guided revenue in the range of $56M - $59M for the period.
Compared to prior guidance, Puma Biotechnology lowered its revenue forecast from a prior range of $224M - $231M.
Puma Biotechnology has issued 30 guidance updates between March 2, 2023 and August 6, 2026. During this period, the company raised its outlook 8 times and lowered it 14 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.07 | $-0.14 | $0.21 | $0.08 |
| Actual | $0.19 | $-0.04 | $0.29 | $0.21 |
| Surprise | +171.4% | +71.4% | +38.1% | +162.5% |
| Revenue | ||||
| Estimate | $53.1M | $41.4M | $68.3M | $49.9M |
| Actual | $53.6M | $44.8M | $75.5M | $54.5M |
| Surprise | +1.01% | +8.10% | +10.5% | +9.11% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.11 | $0.25 | $0.04 | $0.07 |
| Revenue | ||||
| Consensus | $57.4M | $14.0M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $0.19 | $0.07 | 171.4 % |
| Q1 | May 7, 2026 | $-0.04 | $-0.14 | 71.4 % |
| Q4 | Feb 26, 2026 | $0.29 | $0.21 | 38.1 % |
| Q3 | Nov 6, 2025 | $0.21 | $0.08 | 162.5 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $53.60M | $53.07M | 1.01 % |
| Q1 | May 7, 2026 | $44.80M | $41.44M | 8.10 % |
| Q4 | Feb 26, 2026 | $75.50M | $68.30M | 10.5 % |
| Q3 | Nov 6, 2025 | $54.50M | $49.95M | 9.11 % |